Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Welcome to the November 2025 Edition of the Affairs PDF – your all-inclusive monthly guide to…
The Reserve Bank of India (RBI) recently announced two major liquidity measures, a ₹1 trillion…
The ocean is full of amazing and mysterious creatures, many of which are rarely seen…
Russian President Vladimir Putin’s 2025 state visit to India marked a major diplomatic milestone, reviving…
In a major boost to Digital India, the Ministry of Electronics and Information Technology (MEITY)…
In an age where technology and finance intersect at lightning speed, Luana Lopes Lara, a…